IDEAYA Biosciences Aktie

21,20 EUR +1,20 EUR +6,00 %

24.07.2025

BMN

24,82 USD +1,22 USD +5,17 %

24.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.1,76 Mrd. EUR

Div. Rendite0,00%

WKNA2PJPB

ISINUS45166A1025

SymbolIDYA

IDEAYA Biosciences Aktien News

Sortieren:Datum Meistgelesen

12.06.23PR NewswireIDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

30.05.23PR NewswireIDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events

26.05.23PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22.05.23PR NewswireIDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

16.05.23PR NewswireIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

10.05.23finanzen.netIDEAYA Biosciences stellte das Zahlenwerk zum vergangenen Quartal vor

09.05.23PR NewswireIDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

01.05.23PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event

28.04.23PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

23.04.23PR NewswireIDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line M...

19.04.23PR NewswireIDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors

03.04.23PR NewswireIDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event

14.03.23PR NewswireIDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase

08.03.23finanzen.netIDEAYA Biosciences: Was beim Unternehmen in den jüngsten Büchern steht

07.03.23PR NewswireIDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update

01.03.23PR NewswireIDEAYA Biosciences to Participate in Investor Conferences in March 2023

16.02.23PR NewswireIDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit

01.02.23PR NewswireIDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

09.01.23PR NewswireIDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

03.01.23PR NewswireIDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

19.12.22PR NewswireIDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board

12.12.22PR NewswireIDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

05.12.22PR NewswireIDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma

29.11.22PR NewswireIDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022

28.11.22PR NewswireIDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

09.11.22finanzen.netIDEAYA Biosciences: Bilanzvorlage zum letzten Quartal

08.11.22PR NewswireIDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

01.11.22PR NewswireIDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences

18.10.22PR NewswireIDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

11.09.22PR NewswireIDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

06.09.22PR NewswireIDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

30.08.22PR NewswireIDEAYA Biosciences to Participate in Investor Conferences in September 2022

29.08.22PR NewswireIDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate

16.08.22finanzen.netIDEAYA Biosciences legte Quartalsergebnis vor

15.08.22PR NewswireIDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

27.07.22PR NewswireIDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation

27.07.22PR NewswireIDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

11.05.22finanzen.netIDEAYA Biosciences: So schnitt der Konzern im vergangenen Quartal ab

16.03.22finanzen.netIDEAYA Biosciences legte Quartalsergebnis vor

14.03.22finanzen.netAusblick: IDEAYA Biosciences präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.